Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
Study Results
Related Studies
Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis
This study has been completed.
Study NCT01033825 Information provided by Sunovion
First Received on December 16, 2009. Last Updated on July 17, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Perennial Allergic Rhinitis
Additional conditions recognized in this trial
Rhinitis
Rhinitis, Allergic, Perennial
More general conditions related to this trial
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Nose Diseases
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Respiratory Tract Diseases
Respiratory Tract Infections
Interventions listed in this trial
HFA Nasal Aerosol placebo
AQ Nasal Spray Placebo
Placebo plus Dexamethasone HFA
Placebo AQ plus Dexamethasone 6 mg
Additional drug interventions recognized in this trial
BB 1101
Ciclesonide
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
More general drug interventions related to this trial
Anti-Allergic Agents
Anti-Inflammatory Agents
Antiemetics
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Autonomic Agents
Central Nervous System Agents
Enzyme Inhibitors
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Sunovion
Back to top of Main Content
